The startup operates a biotechnology platform that utilizes synthetic biology and bio-foundry services to address environmental degradation through sustainable practices. By providing tailored solutions for environmental challenges, the company enables clients to enhance their ecological impact and contribute to a sustainable future.

Celaid Therapeutics develops regenerative medicine products using human hematopoietic stem cells sourced from umbilical cord and peripheral blood. The company focuses on creating next-generation cell therapies for blood cancers and genetic disorders by employing a proprietary method for the large-scale amplification of functional stem cells without animal-derived components.

Cyto-Facto develops and manufactures CAR-T cell therapies and mesenchymal stem cell products to provide targeted treatments for various cancers and regenerative medicine applications. The company aims to enhance patient outcomes in Japan and beyond through the reliable delivery of cell and gene therapy products.

The startup offers a health application that utilizes cognitive-behavioral therapy techniques to help users manage headache symptoms by identifying and modifying behavioral patterns. This smartphone app connects daily life with medical care, providing users with effective treatment options for migraines.

Immunorock develops an oral immunotherapy platform utilizing bifidobacterium to create vaccines for cancer treatment and coronavirus prevention. This approach aims to provide patients with a more accessible and less invasive treatment option, enhancing their quality of life.

Language IO provides an AI‑driven translation platform that integrates directly into major CRM and support tools, enabling real‑time translation of tickets, attachments, and knowledge‑base content across 150+ languages. The service ensures zero‑data‑retention compliance, uses a self‑improving glossary for brand‑consistent terminology, and automatically selects the optimal language model to keep agents focused on empathy while reducing handling time.

The startup develops targeted therapeutic methods that focus on pathogenic auto-antibodies, conducting research to understand the pathology of diseases linked to these antibodies. By creating specific treatments, the company aims to enhance patient health outcomes in conditions driven by auto-antibody activity.

The startup develops oligonucleotide therapeutics utilizing a licensed cross-linked modified nucleic acid technology that binds strongly to target mRNA, enhancing drug efficacy while minimizing hepatotoxicity risks. This approach provides hospitals with effective treatment alternatives for patients facing diseases that currently lack viable drug options.

Optieum Biotechnologies develops antibody-based therapies utilizing the Eumbody System to create optimized single-chain variable fragments (scFvs) for generating CAR-T cells with enhanced anti-tumor efficacy. Their technology addresses the challenge of treating refractory cancers by improving the proliferation and longevity of CAR-T cells, leading to better patient outcomes and reduced side effects.

Pittan develops high-speed sweat analysis kits that optimize nutritional balance by providing precise insights into individual health metrics. This technology enables users to visualize their physiological state accurately, enhancing personal well-being and lifestyle choices.

The startup develops a bioinformatics platform that utilizes DNA sequence manipulation techniques, including alignment, variant calling, and functional annotation, to identify genes associated with specific functions. This enables biotechnology and pharmaceutical companies to conduct mutational analysis for verifying genetic modifications, thereby enhancing product design and accelerating research timelines.

SecureNavi develops software tools that automate information security management systems, enabling organizations to streamline compliance and risk assessment processes. Their solutions provide real-time monitoring and reporting, significantly reducing the time and resources needed for security audits.

The startup offers a hands-free authentication platform that utilizes precise position measurement technology to determine user location through Bluetooth connections. This enables contactless identification while keeping smartphones in bags or pockets, minimizing misidentification and recognition errors.

The startup has developed a genetic engineering platform that enables long-chain DNA synthesis for the production of microbes and combinatorial DNA libraries. This technology addresses the limitations of traditional DNA synthesis methods, facilitating more efficient and scalable genetic engineering applications for medical professionals.

TCN Prime develops and sells medical devices, including ECMO and BAV catheters, designed to minimize patient risk while ensuring ease of use and high safety standards for healthcare professionals. The company addresses unmet clinical needs in cardiology by providing effective solutions that enhance patient outcomes during critical procedures.

TearExo Inc. has developed a research platform that utilizes tear fluid for the detection of cancer, providing a non-invasive alternative to traditional blood tests. This approach simplifies specimen collection, reduces appointment-related barriers, and enhances patient self-management in cancer screening.

TelaAxon develops artificial intelligence technology focused on enhancing operational sustainability through improved human-AI interaction. The platform addresses challenges related to safety and wellness in various industries by optimizing workflows and reducing operational risks.

The startup specializes in developing gene therapy treatments targeting the RHO rhodopsin gene mutation, a leading cause of inherited retinitis pigmentosa. This approach provides patients with a targeted therapeutic option to address vision loss associated with this genetic condition.

The startup develops alpha nuclear medicine therapy using astatine compounds to target and treat cancer cells with precision. By focusing on low-molecular-weight and antibody-introduced formulations, the company aims to enhance treatment efficacy and minimize side effects for patients undergoing cancer therapy.